Q2 EPS Estimate for Rigel Pharmaceuticals Boosted by Analyst

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities research analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a report issued on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $2.52 for the quarter, up from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ FY2025 earnings at $3.98 EPS and FY2026 earnings at $2.78 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.49. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. The firm had revenue of $53.33 million for the quarter, compared to analysts’ expectations of $43.87 million. During the same period in the previous year, the firm posted ($0.50) EPS.

Several other analysts also recently commented on the company. B. Riley increased their target price on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. StockNews.com cut shares of Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th. Citigroup raised their price objective on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald upped their target price on shares of Rigel Pharmaceuticals from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $36.40.

Rigel Pharmaceuticals Stock Performance

NASDAQ:RIGL opened at $18.81 on Friday. The firm has a market cap of $336.08 million, a P/E ratio of 134.37 and a beta of 1.34. The firm has a 50-day simple moving average of $18.57 and a two-hundred day simple moving average of $19.79. Rigel Pharmaceuticals has a fifty-two week low of $7.48 and a fifty-two week high of $29.82.

Institutional Trading of Rigel Pharmaceuticals

Hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new stake in Rigel Pharmaceuticals during the fourth quarter worth approximately $63,000. US Bancorp DE raised its position in Rigel Pharmaceuticals by 57.4% during the 1st quarter. US Bancorp DE now owns 5,120 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 1,868 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Rigel Pharmaceuticals by 65.9% during the 1st quarter. New York State Common Retirement Fund now owns 5,536 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 2,200 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Rigel Pharmaceuticals by 44.5% during the fourth quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 2,648 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Rigel Pharmaceuticals by 42.8% during the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 2,827 shares during the last quarter. 66.23% of the stock is owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.